Latest Videos
Panelists discuss the efficacy of the INSTI and NNRTI 2-drug regimen dolutegravir-rilpivirine and results of the SWORD-1 and SWORD-2 studies.
Thomas Lodise, PharmD, PhD, discusses why "time to clinical response" is a valuable metric to use in clinical studies.
Laura Waters, MD, FRCP, a consultant physician in the GU and HIV Division at Mortimer Market Center, explains why it is too soon to label the remission as a cure.
Paul Sax, MD, clinical director in the Division of Infectious Diseases at Brigham and Women's Hospital, reacts to the ATLAS and FLAIR studies on long-acting injectable therapy.
Big advances in treatment can't make up for an inability to stop new infections, which number 5,000 per day worldwide.